GammaTile Shows Promise in Newly Diagnosed Glioblastoma
PROVIDENCE, R.I., August 18, 2026 GT Medical Technologies, Inc. announced new clinical findings suggesting that its GammaTile® targeted radiation...
Neuro-oncology
Advertisement
Belay Diagnostics Reports Strong Clinical Utility for Summit 2.0
CHICAGO, July 21, 2026 Belay Diagnostics has announced the publication of a peer-reviewed clinical utility study demonstrating that its...
Nuvation Bio Expands Safusidenib Program with Strong Phase II Data
NEW YORK, July 20, 2026 Nuvation Bio Inc. has announced positive updated Phase II clinical data for safusidenib, its...
Plus Therapeutics Reinforces CNSide Clinical Value Following NCCN Guideline Update
HOUSTON, July 14, 2026 Plus Therapeutics highlighted updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for...
Grey Matters Receives First Brain-Dedicated PET Scanner
VANCOUVER, British Columbia, July 6, 2026 Grey Matters Health Inc. announced the delivery of its first FDA-cleared CareMiBrain™ brain-dedicated...
Advertisements
Sapience Reports Positive Glioblastoma Trial Data
TARRYTOWN, N.Y., May 21, 2026 Sapience Therapeutics has announced encouraging updated clinical data from its ongoing Phase 2 trial...
Belay Diagnostics Summit Improves CNS Cancer Detection
CHICAGO, United States – May 6, 2026 Belay Diagnostics has announced new peer-reviewed clinical data demonstrating that its Belay...
MediciNova Advances Brain Metastasis Therapy With MN-166
LA JOLLA, Calif., April 27, 2026 MediciNova, Inc. has announced a major scientific breakthrough in the treatment of brain...
Telix Doses First Patient in Phase 3 Glioblastoma Trial
Melbourne, Australia & Indianapolis, Indiana, U.S. | April 15, 2026 Telix Pharmaceuticals has announced a major clinical milestone with...
Alpheus Medical Starts Phase 2b Trial in Glioblastoma
CHANHASSEN, Minnesota, April 9, 2026 Alpheus Medical, Inc. has announced the initiation of its Phase 2b randomized clinical trial...
Advertisement
